Pharma Equity Group A/S

PEG A

DK0061155009

Investment Holding Companies

Market Closed - Nasdaq Copenhagen Other stock markets 08:50:00 28/06/2024 pm IST			5-day change	1st Jan Change
0.296 ^DKK	+9.63%		+24.37%	-31.16%

17/05	Pharma Equity Group A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
16/05	Pharma Equity Group A/S Maintains Group Earnings Guidance for the Full Year of 2024	CI

Pharma Equity Group A/S Maintains Group Earnings Guidance for the Full Year of 2024

May 16, 2024 at 10:57 am IST

Pharma Equity Group A/S maintains group earnings guidance for the full year of 2024. For the period, the company maintains the previously announced guidance, a loss before tax in the range of DKK 24 million to DKK 29 million. The outlook does not reflect any gains/losses in connection with the recovery of the Portinho receivable.

Latest news about Pharma Equity Group A/S

Pharma Equity Group A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	17/05	CI
Pharma Equity Group A/S Maintains Group Earnings Guidance for the Full Year of 2024	16/05	CI
Pharma Equity Group A/S announced that it expects to receive DKK 1 million in funding	16/05	CI
Pharma Equity Group A/S announced that it has received DKK 7.6 million in funding	10/04	CI
Pharma Equity Group?s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company?s patented drug candidate RNX-051	05/04	CI
Pharma Equity Group A/S Reports Earnings Results for the Full Year Ended December 31, 2023	20/03	CI
Pharma Equity Group A/S Provides Group Earnings Guidance for the Full Year 2024	20/03	CI
Pharma Equity Group A/S announced that it expects to receive DKK 7.1 million in funding	07/02	CI
Pharma Equity Group A/S announced that it has received DKK 8.914795 million in funding	25/01	CI
Pharma Equity Group's Subsidiary (Reponex Pharmaceuticals A/S) Receives Notification from the European Patent Office	22/01	CI
Pharma Equity Group A/S announced that it expects to receive DKK 8.914795 million in funding	22/01	CI
Pharma Equity Group A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	18/01	CI
Pharma Equity Group Unit Meets Primary Endpoints in Colon Cancer Treatment Trial	16/11	MT
Pharma Equity Group A/S Announces Positive Preliminary Results from the Phase-2 Clinical Trial	16/11	CI
Pharma Equity Group A/S Approves Board Appointments	02/11	CI
Pharma Equity Group?S Subsidiary Company Reponex Pharmaceuticals A/S Receives Grant of Us Patent for A Method of Treatment on Its Topical Wound-Healing Composition	31/23/31	CI
Pharma Equity Group A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	16/23/16	CI
Reponex Pharmaceuticals Set for US Patent for Chronic Wound Treatment Method	15/23/15	MT
Pharma Equity Group A/S Announces Board Changes	15/23/15	CI
Reponex Pharmaceuticals A/S Announces CEO Changes	14/23/14	CI
Reponex Pharmaceuticals A/S Names Dr Christopher M Burton MD, PhD as Chief Medical Officer	14/23/14	CI
Pharma Equity Group A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	10/23/10	CI
Pharma Equity Group A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	10/23/10	CI
Pharma Equity Group A/S Reports Earnings Results for the Full Year Ended December 31, 2022	31/23/31	CI
Reponex Pharmaceuticals A/S completed the acquisition of Pharma Equity Group A/S.	24/23/24	CI

Chart Pharma Equity Group A/S

Duration

Period

More charts

Company Profile

Pharma Equity Group A/S, formerly Blue Vision A/S, is a Denmark-based company. The Company's purpose is, without geographical limitation, to be a holding company for companies with life science activities and to be the biopharmaceutical company that develops the local treatments for serious, acute and chronic inflammatory diseases. The Company's purpose is also to invest in shares admitted to trading on a regulated market place or multilateral trading facility and unlisted capital shares as determined by the board of directors in order to achieve long-term value growth while observing appropriate risk diversification as well as other related businesses.

Sector

Investment Holding Companies

Calendar

16/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Holding Companies

	1st Jan change	Capi.
PHARMA EQUITY GROUP A/S	-31.16%	4.35Cr
INVESTOR AB	+24.28%	8.36TCr
KOÇ HOLDING	+59.94%	1.76TCr
INVESTMENT AB LATOUR	+9.11%	1.73TCr
AB INDUSTRIVÄRDEN	+9.64%	1.46TCr
L E LUNDBERGFÖRETAGEN AB	-4.41%	1.23TCr
BAJAJ HOLDINGS & INVESTMENT LIMITED	+11.19%	1.14TCr
HAL TRUST	-0.70%	1.09TCr
MERITZ FINANCIAL GROUP INC.	+33.84%	1.06TCr
SK SQUARE CO., LTD.	+90.11%	976.77Cr